DGN462 - CAS 1394079-41-4
  1. Home
  2. Products
  3. ADCs Cytotoxin
  4. DGN462

DGN462 - CAS 1394079-41-4 Catalog number: BADC-01401

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

DGN462 is a potent DNA alkylating agent with antitumor activity, such as against acute myeloid leukemia (AML). DGN462 can be used as an ADC toxin molecule to synthesize ADC.

Category
ADCs Cytotoxin
Product Name
DGN462
CAS
1394079-41-4
Catalog Number
BADC-01401
Molecular Formula
C53H59N5O9S
Molecular Weight
942.13
DGN462

Ordering Information

Catalog Number Size Price Quantity
BADC-01401 -- $--
Inquiry
Description
DGN462 is a potent DNA alkylating agent with antitumor activity, such as against acute myeloid leukemia (AML). DGN462 can be used as an ADC toxin molecule to synthesize ADC.
Synonyms
DGN-462; IMGN-779; IMGN779-linker; (5aS)-10-Methoxy-9-({3-[{2-[2-(2-methoxyethoxy)ethoxy]ethyl}(2-methyl-2-sulfanylpropyl)amino]-5-({[(5aS)-10-methoxy-12-oxo-5a,6,7,12-tetrahydro-5H-indolo[2,1-c][1,4]benzodiazepin-9-yl]oxy}methyl)benzyl}oxy)-5,5a-dihydro-12H-indolo[2,1-c][1,4]benzodiazepin-12-one; 6H-Indolo[2,1-c][1,4]benzodiazepin-6-one, 9-[[3-[[[(12aS)-12a,13-dihydro-8-methoxy-6-oxo-6H-indolo[2,1-c][1,4]benzodiazepin-9-yl]oxy]methyl]-5-[(2-mercapto-2-methylpropyl)[2-[2-(2-methoxyethoxy)ethoxy]ethyl]amino]phenyl]methoxy]-11,12,12a,13-tetrahydro-8-methoxy-, (12aS)-; (12aS)-9-[[3-[[[(12aS)-12a,13-Dihydro-8-methoxy-6-oxo-6H-indolo[2,1-c][1,4]benzodiazepin-9-yl]oxy]methyl]-5-[(2-mercapto-2-methylpropyl)[2-[2-(2-methoxyethoxy)ethoxy]ethyl]amino]phenyl]methoxy]-11,12,12a,13-tetrahydro-8-methoxy-6H-indolo[2,1-c][1,4]benzodiazepin-6-one
IUPAC Name
(12aS)-9-[[3-[[(12aS)-8-methoxy-6-oxo-11,12,12a,13-tetrahydroindolo[2,1-c][1,4]benzodiazepin-9-yl]oxymethyl]-5-[2-[2-(2-methoxyethoxy)ethoxy]ethyl-(2-methyl-2-sulfanylpropyl)amino]phenyl]methoxy]-8-methoxy-12a,13-dihydroindolo[2,1-c][1,4]benzodiazepin-6-one
Canonical SMILES
CC(C)(CN(CCOCCOCCOC)C1=CC(=CC(=C1)COC2=C(C=C3C(=C2)N=CC4CC5=CC=CC=C5N4C3=O)OC)COC6=C(C=C7C(=C6)NCC8CC9=CC=CC=C9N8C7=O)OC)S
InChI
InChI=1S/C53H59N5O9S/c1-53(2,68)33-56(14-15-64-18-19-65-17-16-61-3)38-21-34(31-66-49-27-43-41(25-47(49)62-4)51(59)57-39(29-54-43)23-36-10-6-8-12-45(36)57)20-35(22-38)32-67-50-28-44-42(26-48(50)63-5)52(60)58-40(30-55-44)24-37-11-7-9-13-46(37)58/h6-13,20-22,25-29,39-40,55,68H,14-19,23-24,30-33H2,1-5H3/t39-,40-/m0/s1
InChIKey
DOKWDOLZCMETIJ-ZAQUEYBZSA-N
Density
1.31±0.1 g/cm3
Solubility
Soluble in DMSO
Purity
≥95%
Storage
Store at 2-8°C for short term (days to weeks) or -20°C for long term (months to years)
1.The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models
Haematologica . 2019 Aug;104(8):1633-1639. doi: 10.3324/haematol.2018.211011. Epub 2019 Feb 7.
Antibody-drug conjugates (ADC) are a novel way to deliver potent cytotoxic compounds to cells expressing a specific antigen. Four ADC targeting CD19, including SAR3419 (coltuximab ravtansine), have entered clinical development. Here, we present huB4-DGN462, a novel ADC based on the SAR3419 anti-CD19 antibody linked via sulfo-SPDB to the potent DNA-alkylating agent DGN462. huB4-DGN462 had improved in vitro anti-proliferative and cytotoxic activity compared to SAR3419 across multiple B-cell lymphoma and human acute lymphoblastic leukemia cell lines. In vivo experiments using lymphoma xenografts models confirmed the in vitro data. The response of B-cell lymphoma lines to huB4-DGN462 was not correlated with CD19 expression, the presence of BCL2 or MYC translocations, TP53 inactivation or lymphoma histology. In conclusion, huB4-DGN462 is an attractive candidate for clinical investigation in patients with B-cell malignancies.
The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Calculate
The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Calculate

Related Products

Triptolide
Triptolide
(CAS: 38748-32-2)
Topotecan
Topotecan
(CAS: 123948-87-8)
Epirubicin
Epirubicin
(CAS: 56420-45-2)
Vipivotide tetraxetan
Vipivotide tetraxetan
(CAS: 1702967-37-0)
17-AEP-GA
17-AEP-GA
(CAS: 75747-23-8)
Actinomycin D
Actinomycin D
(CAS: 50-76-0)
Historical Records: INNO-206 | Mal-PEG4-bis-PEG3-DBCO | DGN462
Why Choose BOC Sciences?

Customer Support

Providing excellent 24/7 customer service and support

Project Management

Offering 100% high-quality services at all stages

Quality Assurance

Ensuring the quality and reliability of products or services

Global Delivery

Ensuring timely delivery of products worldwide

Featured Services
cGMP Grade Products

BOC Sciences offers comprehensive services for ADC manufacturing, including antibody modification, linker chemistry, payload conjugation, and formulation development. In particular, our payload-linker customization service offers a convenient and fast raw material channel for many ADC researchers.
Site-Specific Conjugation

BOC Sciences provides one-stop site-specific conjugation services for amino acids, glycans, unnatural amino acids, and short peptide tags. In addition, cysteine conjugation, lysine conjugation, enzymatic conjugation, thio-engineered antibody can also be obtained quickly.
Linkers for Bioconjugation

BOC Sciences offers a full range of linkers, including peptide linkers, PEG linkers, click chemistry, PROTAC linkers, non-cleavable linkers, etc. We also provide custom development services for chemically labile linkers and enzymatically cleavable linkers.
ADC Targets
Questions & Comments
Verification code
Send Inquiry
Verification code
Inquiry Basket
loading Loading ......
Delete selectedGo to checkout